These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27514622)

  • 21. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.
    Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M
    Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
    Varedi D; Kovacsovics T; Downs Kelly E; Abraham J; Cowley J; Barrell K; Revelo MP; Stehlik J; Drakos S; Marrouche N; Wilson B; Swanson EA; Fang J; Nativi-Nicolau J
    Circ Heart Fail; 2018 Jul; 11(7):e004812. PubMed ID: 29921704
    [No Abstract]   [Full Text] [Related]  

  • 24. Early identification of transthyretin-related hereditary cardiac amyloidosis.
    Arbustini E; Merlini G
    JACC Cardiovasc Imaging; 2014 May; 7(5):511-4. PubMed ID: 24831211
    [No Abstract]   [Full Text] [Related]  

  • 25. [Problems of diagnostics and treatment of transtiretinum amyloidosis with destruction of the heart in the elderly: Clinical experience.].
    Boldueva SA; Petrova VB; Khavinson VK; Samohvalova MV; Petrova AI
    Adv Gerontol; 2019; 32(1-2):137-144. PubMed ID: 31228380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transthyretin amyloid cardiomyopathy.
    Garcia-Pavia P; Domínguez F; Gonzalez-Lopez E
    Med Clin (Barc); 2021 Feb; 156(3):126-134. PubMed ID: 33138983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding and recognizing cardiac amyloidosis.
    McVeigh T; Tennyson C
    JAAPA; 2020 Oct; 33(10):16-20. PubMed ID: 32941304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multimodality imaging of simultaneous occurrence of cardiac transthyretin amyloidosis and cardiac sarcoidosis.
    Elchinova E; Banz Y; Zbinden S; Caobelli F; Gräni C
    J Nucl Cardiol; 2023 Oct; 30(5):2207-2208. PubMed ID: 35974261
    [No Abstract]   [Full Text] [Related]  

  • 30. New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis.
    Perlini S; Mussinelli R; Salinaro F
    Eur J Heart Fail; 2021 Feb; 23(2):290-292. PubMed ID: 33527646
    [No Abstract]   [Full Text] [Related]  

  • 31. Biology or Disparity? Untangling Racial Differences in Val122Ile Transthyretin Cardiac Amyloidosis.
    Kittleson MM
    J Card Fail; 2022 Jun; 28(6):960-962. PubMed ID: 35041934
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute cardiac failure secondary to senile systemic amyloidosis.
    Bodard Q; Roca F; Dilly B; Laurent D; Chassagne P
    Age Ageing; 2016 Nov; 45(6):908-909. PubMed ID: 27103598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transthyretin Cardiac Amyloidosis in the Elderly-Tip of a Heart Failure Iceberg?
    Alexander KM; Dorbala S
    JAMA Cardiol; 2021 Aug; 6(8):979-980. PubMed ID: 34037661
    [No Abstract]   [Full Text] [Related]  

  • 34. Cardiac amyloidosis: an update on diagnosis, current therapy, and future directions.
    Khedraki R
    Curr Opin Cardiol; 2022 May; 37(3):272-284. PubMed ID: 35612939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser).
    Patel K; Tagoe C; Bieri P; Weidenheim K; Tauras JM
    Amyloid; 2018 Sep; 25(3):211-212. PubMed ID: 30039724
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis.
    Ripoll-Vera T; Buades J; Cisneros E; Gómez Y; Núñez J; Raya M
    Rev Esp Cardiol (Engl Ed); 2019 Jan; 72(1):92-94. PubMed ID: 29223374
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
    Gopal DM; Ruberg FL; Siddiqi OK
    Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Untangling Wild-Type Transthyretin Amyloidosis.
    Judge DP; Lee YZ; Sharma K
    J Am Coll Cardiol; 2016 Sep; 68(10):1021-3. PubMed ID: 27585506
    [No Abstract]   [Full Text] [Related]  

  • 39. Echocardiographic tools for prognostic stratification in transthyretin cardiac amyloidosis: a new arrow in the quiver.
    Citro R; Silverio A; Bellino M
    Eur Heart J Cardiovasc Imaging; 2024 Mar; 25(4):480-481. PubMed ID: 38279943
    [No Abstract]   [Full Text] [Related]  

  • 40. CMR and amyloid cardiomyopathy: are we getting closer to the biology?
    Kwong RY; Jerosch-Herold M
    JACC Cardiovasc Imaging; 2014 Feb; 7(2):166-8. PubMed ID: 24524743
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.